A combination of 2aG4 -- a monoclonal antibody -- and PRIMA-1 -- a small molecular drug -- was found effective in inhibiting tumor development by targeting mutated p53 protein and tumor blood vessels in two breast cancer cell lines, a U.S. study found. The combination therapy, which is less toxic to healthy cells or organs, "could define a new strategy for suppression of advanced breast cancers," one of the researchers said.

Full Story:

Related Summaries